Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
President Trump has nominated Heidi Overton, MD, PhD — currently deputy director of the White House Domestic Policy Council — to be the next FDA commissioner. If confirmed by the Senate, she'll inherit a politically charged agency that has lost over 3,000 staff and faces pressure on vaccine policy, abortion pills, drug approvals, and food safety. Her confirmation is expected to face scrutiny from both sides of the aisle.
President Trump has nominated Heidi Overton, MD, PhD — a deputy director of the White House Domestic Policy Council and former chief policy officer at the America First Policy Institute — to serve as the next FDA commissioner. Overton trained in general surgery at Johns Hopkins and holds a doctorate in clinical investigation. She has been a visible champion of Trump's second-term health agenda, including his controversial executive order to split the MMR vaccine into three separate shots.
If confirmed by the narrowly Republican-led Senate, Overton will inherit a deeply challenged agency. The FDA has shed more than 3,000 staff over the past year, and her predecessor Marty Makary resigned in May amid clashes with White House advisers and industry backlash. She'll face pressure from multiple directions: traditional Republicans pushing deregulation, RFK Jr.'s MAHA movement, abortion opponents, and biotech companies frustrated by stalled drug reviews.
Her confirmation is far from guaranteed — Democratic senators have already pushed back on the pick, and Senate HELP Committee Chair Sen. Bill Cassidy (R-LA) has been critical of the administration's vaccine skepticism.
Key Takeaways:
Why it matters: The FDA commissioner shapes drug approvals, vaccine policy, and food safety for hundreds of millions of Americans. With the agency already politically strained and significantly understaffed, the choice of its next leader carries major consequences for public health.
